ScholarLens Back to search
2006•Zhongguo xin yao zazhiRequires access

Clinical observations of domestic risperidone for the treatment of schizophrenia

Fude Yang

Open publisher page 0 citations

Abstract

Objective:To assess safety and efficacy of domestic risperidone for the treatment of schizophrenia. Methods:30 in-hospital patients with schizophrenia orally received risperidone 1～6 mg daily for 6 weeks in a conventional clinical practice setting. Efficacy was evaluated using the Positive and Negative Symptom Scale (PANSS) and adverse reaction using the Treatment Emergent Symptom Scale (TESS). Results:At the end of the therapy, the risperidone-treated patients had cure rate 30% , marked improvement rate of 46. 7% and improvement rate of 86. 7% . The patient's onset of the therapeutic response on risperidone was in one week after the dosing.The optimal dose was in a range of 2～4 mg·d-1. The common side effects included akathisia, dystonia and constipation. Conclusion:Risperi done is effective and safe in the treatment of schizophrenia.

About this research paper

What this paper is about

Objective:To assess safety and efficacy of domestic risperidone for the treatment of schizophrenia. Methods:30 in-hospital patients with schizophrenia orally received risperidone 1～6 mg daily for 6 weeks in a conventional clinical practice setting. Efficacy was evaluated using the Positive and Negative Symptom Scale (PANSS) and adverse reaction using the Treatment Emergent Symptom Scale (TESS). Results:At the end of the therapy, the risperidone-treated patients had cure rate 30% , marked improvement rate of 46. 7% and improvement rate of 86. 7% . The patient's onset of the therapeutic response on risperidone was in one week after the dosing.The optimal dose was in a range of 2～4 mg·d-1. The common side effects included akathisia, dystonia and constipation. Conclusion:Risperi done is effective and safe in the treatment of schizophrenia.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To assess safety and efficacy of domestic risperidone for the treatment of schizophrenia. Methods:30 in-hospital patients with schizophrenia orally received risperidone 1～6 mg daily for 6 weeks in a conventional clinical practice setting. Efficacy was evaluated using the Positive and Negative Symptom Scale (PANSS) and adverse reaction using the Treatment Emergent Symptom Scale (TESS). Results:At the end of the therapy, the risperidone-treated patients had cure rate 30% , marked improvement rate of 46. 7% and improvement rate of 86. 7% . The patient's onset of the therapeutic response on risperidone was in one week after the dosing.The optimal dose was in a range of 2～4 mg·d-1. The common side effects included akathisia, dystonia and constipation. Conclusion:Risperi done is effective and safe in the treatment of schizophrenia.

Key concepts: Risperidone, Schizophrenia (object-oriented programming), Akathisia, Adverse effect, Medicine, Positive and Negative Syndrome Scale, Dosing, Clinical efficacy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical observations of domestic risperidone for the treatment of schizophrenia — Research Paper | ScholarLens